ClinicalTrials.gg
CompletedNCT00556998Updated May 5, 2016Results posted

A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents

A Phase 2 interventional study of Voriconazole in Pharmacokinetics, sponsored by Pfizer. Completed at 9 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-05.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
12 Years to 17 Years
Sex
All
01

Study summary

This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • pharmacokinetics and safety data of voriconazole in immunocompromised adolescents
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are expected to develop neutropenia following chemotherapy.
  • Subjects who require treatment for the prevention of systemic fungal infection.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history of severe intolerance of azole antifungal agents.
  • Subjects with documented bacterial or viral infection at the time of study entry who are not responding to appropriate treatment against the infection.
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    1

    Drug: Voriconazole

Interventions

  • Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.

    Also known as: Vfend

06

What researchers measure

Primary outcomes

  1. Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion

  2. Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration

    Time frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion

  3. Time to Reach Cmax (Tmax) Following IV Administration

    Time frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion

  4. AUC12,ss Following Oral Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose

  5. Cmax,ss Following Oral Administration

    Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose

  6. Tmax Following Oral Administration

    Time frame: Day 7 (up to Day 30) Predose, 1, 2, 4, 6, 8, and 12 hours postdose

Secondary outcomes

  1. AUC12 Following IV Loading Dose

    AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion

  2. Tmax Following an IV Loading Dose

    Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion

  3. Cmax Following an IV Loading Dose

    Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion

  4. Minimum Observed Plasma Trough Concentration (Cmin)

    Time frame: Day 7 (up to Day 20) for IV; Day 7 (up to Day 30) for oral at predose

  5. AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion

  6. Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

    Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion

  7. Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

    Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion

  8. AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: On Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose

  9. Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

    Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose

  10. Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

    Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose

Other outcomes

  1. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Loading Dose.

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 1

  2. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Steady State

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 7 of IV dosing

  3. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral Dose All Subjects

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 7 Oral dosing

  4. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral 300mg

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 7 oral dosing

  5. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Loading Dose

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 1

  6. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Steady State

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 7 of Intravenous dosing

  7. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax Day 7 Oral All Participants

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 7 of oral dosing

  8. Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax 300 mg Oral Dose

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 7 of oral dosing

07

Results

Posted Mar 16, 2012

Participant flow

Voriconazole Intravenous (IV)
Participant flow — Voriconazole Intravenous (IV)
MilestoneAll Treatments
Started26
Treated26
Completed21
Not completed5
Withdrew: Adverse event1
Withdrew: Other4
Voriconazole Oral
Participant flow — Voriconazole Oral
MilestoneAll Treatments
Started22
Completed20
Not completed2
Withdrew: Adverse event1
Withdrew: Intolerant of oral treatment1

Outcome measures

PrimaryArea Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion
Reported as:
Geometric mean · μg*h/mL
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration
μg*h/mLVoriconazole IV
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration22.39 ± 21.47
PrimaryPeak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Time frame:
Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion
Reported as:
Geometric mean · μg/mL
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
μg/mLVoriconazole IV
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration3.89 ± 2.59
PrimaryTime to Reach Cmax (Tmax) Following IV Administration
Time frame:
Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion
Reported as:
Median · hours
Time to Reach Cmax (Tmax) Following IV Administration
hoursVoriconazole IV
Time to Reach Cmax (Tmax) Following IV Administration1.30 (1.17 to 3.95)
PrimaryAUC12,ss Following Oral Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
AUC12,ss Following Oral Administration
μg*h/mLVoriconazole Oral
AUC12,ss Following Oral Administration16.74 ± 13.50
PrimaryCmax,ss Following Oral Administration
Time frame:
Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Cmax,ss Following Oral Administration
μg/mLVoriconazole Oral
Cmax,ss Following Oral Administration2.35 ± 1.41
PrimaryTmax Following Oral Administration
Time frame:
Day 7 (up to Day 30) Predose, 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Median · hours
Tmax Following Oral Administration
hoursVoriconazole Oral
Tmax Following Oral Administration2.00 (0.67 to 8.10)
SecondaryAUC12 Following IV Loading Dose

AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion
Reported as:
Geometric mean · μg*h/mL
AUC12 Following IV Loading Dose
μg*h/mLVoriconazole IV
AUC12 Following IV Loading Dose9.14 ± 4.90
SecondaryTmax Following an IV Loading Dose
Time frame:
Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion
Reported as:
Median · hours
Tmax Following an IV Loading Dose
hoursVoriconazole IV
Tmax Following an IV Loading Dose1.97 (1.90 to 2.08)
SecondaryCmax Following an IV Loading Dose
Time frame:
Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion
Reported as:
Geometric mean · μg/mL
Cmax Following an IV Loading Dose
μg/mLVoriconazole IV
Cmax Following an IV Loading Dose2.25 ± 0.86
SecondaryMinimum Observed Plasma Trough Concentration (Cmin)
Time frame:
Day 7 (up to Day 20) for IV; Day 7 (up to Day 30) for oral at predose
Reported as:
Geometric mean · μg/mL
Minimum Observed Plasma Trough Concentration (Cmin)
μg/mLAll Treatments
IV Day 7 (up to Day 20) (n=21)1.05 ± 1.85
Oral Day 7 (up to Day 30) (n=19)0.72 ± 0.81
SecondaryAUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion
Reported as:
Geometric mean · μg*h/mL
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
μg*h/mLVoriconazole IV
Day 121.18 ± 6.80
Day 7 (up to Day 20)36.21 ± 9.20
SecondaryCmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame:
Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion
Reported as:
Geometric mean · μg/mL
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
μg/mLVoriconazole IV
Day 12.50 ± 0.84
Day 7 (up to Day 20)3.48 ± 0.73
SecondaryTmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame:
Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion
Reported as:
Median · μg*h/mL
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
μg*h/mLVoriconazole IV
Day 14.00 (1.97 to 8.03)
Day 7 (up to Day 20)4.03 (0.00 to 12.10)
SecondaryAUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
On Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
μg*h/mLVoriconazole Oral
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration44.07 ± 13.86
SecondaryCmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame:
Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
μg/mLVoriconazole Oral
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration4.44 ± 1.43
SecondaryTmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame:
Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Median · hours
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
hoursVoriconazole Oral
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration5.97 (1.00 to 8.10)
Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Loading Dose.

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 1
Reported as:
Geometric mean · mcg*hr/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Steady State

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 7 of IV dosing
Reported as:
Geometric mean · mcg*hr/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral Dose All Subjects

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 7 Oral dosing
Reported as:
Geometric mean · mcg*hr/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral 300mg

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 7 oral dosing
Reported as:
Geometric mean · mcg*hr/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Loading Dose

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 1
Reported as:
Geometric mean · mcg/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Steady State

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 7 of Intravenous dosing
Reported as:
Geometric mean · mcg/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax Day 7 Oral All Participants

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 7 of oral dosing
Reported as:
Geometric mean · mcg/mL

Results for this outcome have not been posted.

Other pre-specifiedPharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax 300 mg Oral Dose

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 7 of oral dosing

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole IV—4/26 (15.4%)26/26 (100%)
Voriconazole Oral—4/22 (18.2%)22/22 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventVoriconazole IVVoriconazole Oral
NauseaGastrointestinal disorders0/261/22
VomitingGastrointestinal disorders0/261/22
Acute graft versus host disease in intestineImmune system disorders0/261/22
Acute graft versus host disease in liverImmune system disorders0/261/22
Blood bilirubin increasedInvestigations0/261/22
Decreased appetiteMetabolism and nutrition disorders0/261/22
DepressionPsychiatric disorders0/261/22
Cystitis haemorrhagicRenal and urinary disorders0/261/22
Renal failure acuteRenal and urinary disorders1/261/22
Respiratory failureRespiratory, thoracic and mediastinal disorders0/261/22
Most frequent other events
Showing 10 of 222
Most frequent other events
EventVoriconazole IVVoriconazole Oral
PyrexiaGeneral disorders13/265/22
Mucosal inflammationGeneral disorders11/269/22
NauseaGastrointestinal disorders6/266/22
DysuriaRenal and urinary disorders1/266/22
HypertensionVascular disorders4/266/22
DiarrhoeaGastrointestinal disorders5/265/22
VomitingGastrointestinal disorders5/265/22
Oxygen saturation decreasedInvestigations1/265/22
Fluid retentionMetabolism and nutrition disorders4/265/22
Bone painMusculoskeletal and connective tissue disorders2/265/22

Baseline characteristics

Age, Customized
Age, Customized(Years)All Treatments
124
1310
>13 to <1712
Sex/Gender, Customized
Sex/Gender, Customized(Participants)All Treatments
Female9
Male17
08

Study locations

9 sites
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70118, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27705, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44106, United States
  • Pfizer Investigational Site
    Portland, Oregon 97239, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232-2195, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76104-2796, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2007
First posted
Nov 12, 2007
Start
Jun 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Mar 16, 2012
Last update
May 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00556998
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 12, 2007
Start date
Jun 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Mar 16, 2012
Last update
May 5, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion